KimeraChems.coUse code GUIDE for 10% OFF
Back to Analytical Reagents
Analytical Reagents

Acetildenafil

Shop Acetildenafil on KimeraChems · code GUIDE (10% off)

Definition

Acetildenafil is a synthetic phosphodiesterase type 5 (PDE5) inhibitor analog researched for its ability to influence the nitric-oxide and cyclic guanosine monophosphate (cGMP) pathway in vascular smooth muscle. In research contexts, it is primarily explored for its potential to increase cGMP signaling by inhibiting PDE5, which may amplify nitric-oxide-mediated vasodilation responses in responsive models. Acetildenafil is commonly discussed as a sildenafil-related analog, with ongoing analytical interest in its potency, selectivity, metabolism, and safety profile relative to better-characterized PDE5 inhibitors.

Available Formats

  • Dry-fill capsules (30 mg per capsule, 60-count / 1.8 g total)
  • Powder (commonly listed as 2 g)

Mechanism of Action

Research suggests Acetildenafil may: Because PDE5 inhibition occurs downstream of nitric-oxide signaling, observed effects depend on baseline nitric-oxide tone, vascular responsiveness, and other variables that influence cGMP dynamics.

  • Inhibit PDE5 and reduce the breakdown of cGMP
  • Increase cGMP signaling downstream of nitric oxide
  • Promote smooth-muscle relaxation in nitric-oxide-responsive tissues
  • Support vasodilation-related endpoints in vascular models
  • Influence hemodynamic variables such as perfusion and pressure in study designs where nitric-oxide signaling is a primary variable

Areas of Investigation

Acetildenafil is commonly studied in

  • PDE5-inhibition assays and comparative-potency studies
  • Vascular-tone and perfusion models
  • Endothelial-function research in which nitric-oxide and cGMP signaling are central
  • Analytical-chemistry and adulterant-screening contexts
  • Metabolism and CYP-mediated biotransformation studies
  • Safety and off-target profiling relative to established PDE inhibitors

Safety Profile

Reported observations include

  • Headache and flushing-like effects consistent with vasodilation
  • Dizziness or lightheadedness in blood-pressure-sensitive models
  • Nasal congestion
  • Gastrointestinal discomfort in some subjects
  • Visual-disturbance signals, particularly where PDE6 cross-activity is a concern
  • Hypotension-related risk signals, especially when combined with nitrates or other strong vasodilators

Interaction Notes

Acetildenafil is often explored alongside variables that influence nitric-oxide signaling and hemodynamic outcomes

Disclaimer

For educational purposes only. Not for human consumption.